View ValuationSavior Lifetec 将来の成長Future 基準チェック /06現在、 Savior Lifetecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 18First quarter 2026 earnings released: EPS: NT$0.29 (vs NT$1.22 in 1Q 2025)First quarter 2026 results: EPS: NT$0.29 (down from NT$1.22 in 1Q 2025). Revenue: NT$233.6m (down 12% from 1Q 2025). Net income: NT$90.2m (down 77% from 1Q 2025). Profit margin: 39% (down from 146% in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 17Full year 2025 earnings released: EPS: NT$1.72 (vs NT$0.57 in FY 2024)Full year 2025 results: EPS: NT$1.72 (up from NT$0.57 in FY 2024). Revenue: NT$1.20b (down 1.3% from FY 2024). Net income: NT$537.4m (up 195% from FY 2024). Profit margin: 45% (up from 15% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$20.80, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 11% over the past three years.お知らせ • Mar 06Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026. Location: 2 floor no,26, nan k`o 3rd rd., tainan city TaiwanNew Risk • Nov 24New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 154% Dividend yield: 2.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risk Dividend is not well covered by cash flows (154% cash payout ratio).Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: NT$0.26 (vs NT$0.14 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.26 (up from NT$0.14 in 3Q 2024). Revenue: NT$282.5m (down 15% from 3Q 2024). Net income: NT$79.9m (up 87% from 3Q 2024). Profit margin: 28% (up from 13% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.069 profit in 2Q 2024)Second quarter 2025 results: NT$0.05 loss per share (down from NT$0.069 profit in 2Q 2024). Revenue: NT$335.5m (down 3.8% from 2Q 2024). Net loss: NT$16.9m (down 177% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Declared Dividend • Jun 28Dividend increased to NT$0.41Dividend of NT$0.41 is 381% higher than last year. Ex-date: 14th July 2025 Payment date: 5th August 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Payout Ratios Payout ratio: 15%. Cash payout ratio: 10%.New Risk • May 31New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 108% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • May 17First quarter 2025 earnings released: EPS: NT$1.22 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$1.22 (up from NT$0.22 in 1Q 2024). Revenue: NT$263.9m (up 1.8% from 1Q 2024). Net income: NT$386.1m (up 443% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 25Savior Lifetec Corporation to Report Q1, 2025 Results on May 02, 2025Savior Lifetec Corporation announced that they will report Q1, 2025 results on May 02, 2025お知らせ • Apr 11Savior Lifetec Corporation Obtains Approval for Marketing in China and Obtains Drug LicenseSavior Lifetec Corporation obtained approval for marketing in China and obtained drug license. SLC's generic drug Ertapenem Sodium for Injection has been approved for drug registration by the NMPA of China, and a drug registration certificate has been obtained. This product is a carbapenem used for the treatment of complicated infections caused by multidrug-resistant bacteria. Indications of the product include: Complicated intra-abdominal infection, Community-acquired pneumonia, Acute pelvic infection, Complicated urinary tract infection, and Complicated skin and soft tissue infection. This product is the first to receive a drug registration certificate in the China market for the Company.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$15.90, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 12% over the past three years.New Risk • Apr 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 30Full year 2024 earnings released: EPS: NT$0.57 (vs NT$0.095 in FY 2023)Full year 2024 results: EPS: NT$0.57 (up from NT$0.095 in FY 2023). Revenue: NT$1.22b (up 16% from FY 2023). Net income: NT$182.4m (up NT$152.4m from FY 2023). Profit margin: 15% (up from 2.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 07Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025. Location: 2 floor no,26, nan k`o 3rd rd., tainan city Taiwanお知らせ • Feb 27Savior Lifetec Corporation to Report Fiscal Year 2024 Results on Mar 06, 2025Savior Lifetec Corporation announced that they will report fiscal year 2024 results on Mar 06, 2025Buy Or Sell Opportunity • Feb 11Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jan 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.4% to NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.052 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.052 loss in 3Q 2023). Revenue: NT$332.5m (up 16% from 3Q 2023). Net income: NT$42.7m (up NT$59.2m from 3Q 2023). Profit margin: 13% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.016 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.07 (up from NT$0.016 in 2Q 2023). Revenue: NT$348.7m (up 56% from 2Q 2023). Net income: NT$21.9m (up 335% from 2Q 2023). Profit margin: 6.3% (up from 2.3% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat.お知らせ • Aug 01Savior Lifetec Corporation to Report Q2, 2024 Results on Aug 08, 2024Savior Lifetec Corporation announced that they will report Q2, 2024 results on Aug 08, 2024Buy Or Sell Opportunity • Jul 09Now 25% undervaluedOver the last 90 days, the stock has risen 7.8% to NT$23.45. The fair value is estimated to be NT$31.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% over the last 3 years. Earnings per share has declined by 38%.Declared Dividend • Jun 28Dividend reduced to NT$0.085Dividend of NT$0.085 is 18% lower than last year. Ex-date: 12th July 2024 Payment date: 5th August 2024 Dividend yield will be 0.3%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 26%. Cash payout ratio: 6%.お知らせ • Jun 27Savior Lifetec Corporation Approves the Cash Dividend, Payable on August 05, 2024Savior Lifetec Corporation at its shareholders’ meeting held on June 26, 2024, approved the cash dividend of TWD 0.0851 per share will be distributed, totaling TWD 27,027,002. Ex-rights (Ex-dividend) date: July 12, 2024. Ex-rights (Ex-dividend) record date: July 20, 2024. Payment date of cash dividend distribution: August 05, 2024.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.22 (vs NT$0.011 loss in 1Q 2023)First quarter 2024 results: EPS: NT$0.22 (up from NT$0.011 loss in 1Q 2023). Revenue: NT$259.2m (up 17% from 1Q 2023). Net income: NT$71.1m (up NT$74.6m from 1Q 2023). Profit margin: 27% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Apr 28Savior Lifetec Corporation to Report Q1, 2024 Results on May 03, 2024Savior Lifetec Corporation announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 03, 2024New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 21Full year 2023 earnings released: EPS: NT$0.09 (vs NT$0.12 in FY 2022)Full year 2023 results: EPS: NT$0.09 (down from NT$0.12 in FY 2022). Revenue: NT$1.05b (down 17% from FY 2022). Net income: NT$30.0m (down 18% from FY 2022). Profit margin: 2.9% (in line with FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.お知らせ • Mar 09Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024. Location: 2F., No. 26, Nanke 3rd Rd., Xinshi Dist., Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 distributable compensation for employees and directors; to consider 2023 Annual Earnings Cash Dividend Distribution Report; to consider Audit Committee’s Review Report; to consider 2023 Business Report and Financial Statements; to consider Company's 2023 earnings distribution; and to consider Lifting the non-competition restriction case of the company’s directors.Reported Earnings • Nov 11Third quarter 2023 earnings released: NT$0.05 loss per share (vs NT$0.42 profit in 3Q 2022)Third quarter 2023 results: NT$0.05 loss per share (down from NT$0.42 profit in 3Q 2022). Revenue: NT$287.2m (down 18% from 3Q 2022). Net loss: NT$16.5m (down 112% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$21.35, the stock trades at a trailing P/E ratio of 71.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 32% over the past three years.Reported Earnings • Aug 05Second quarter 2023 earnings released: EPS: NT$0.02 (vs NT$0.005 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.02 (up from NT$0.005 loss in 2Q 2022). Revenue: NT$223.2m (down 37% from 2Q 2022). Net income: NT$5.03m (up NT$6.56m from 2Q 2022). Profit margin: 2.3% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 29Upcoming dividend of NT$0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 03 August 2023. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.6%).Reported Earnings • Mar 16Full year 2022 earnings released: EPS: NT$0.11 (vs NT$0.031 in FY 2021)Full year 2022 results: EPS: NT$0.11 (up from NT$0.031 in FY 2021). Revenue: NT$1.27b (down 27% from FY 2021). Net income: NT$36.4m (up 266% from FY 2021). Profit margin: 2.9% (up from 0.6% in FY 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 07Second quarter 2022 earnings released: NT$0.005 loss per share (vs NT$0.051 profit in 2Q 2021)Second quarter 2022 results: NT$0.005 loss per share (down from NT$0.051 profit in 2Q 2021). Revenue: NT$356.1m (down 32% from 2Q 2021). Net loss: NT$1.53m (down 109% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Aug 06Savior Lifetec Corporation Appoints as Xu Fang Zhen Head of Internal AuditSavior Lifetec Corporation appointed as Xu Fang Zhen Head of Internal Audit. Name, title, and resume of the new position holder: XU FANG ZHEN, internal audit officer /Deputy Audit Manager of UNISON COMPANY LTD. Effective date is August 5, 2022.お知らせ • Jun 02Savior Lifetec Corporation Announces Appointment of Cheng, Chin-Hwa as Member of the Audit CommitteeSavior Lifetec Corporation announced changes in the members of the audit committee with appointment of Cheng, Chin-Hwa as new member . Date of change is June 1 2022. Resume of the new position holder: Independent director of Chongdah health co. Ltd.Reported Earnings • May 08First quarter 2022 earnings released: NT$0.17 loss per share (vs NT$0.25 profit in 1Q 2021)First quarter 2022 results: NT$0.17 loss per share (down from NT$0.25 profit in 1Q 2021). Revenue: NT$307.3m (down 39% from 1Q 2021). Net loss: NT$54.0m (down 168% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 16Savior Lifetec Corporation Approves the Appointment of Cheng, Chin-Hwa as Members of the Compensation CommitteeSavior Lifetec Corporation approved the appointment of Cheng, Chin-Hwa as members of the compensation Committee. Resume of the new position holder: Independent director of Chongdah health co. Ltd. Effective date of the new member is April 15, 2022.Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: NT$0.03 (down from NT$0.84 in FY 2020). Revenue: NT$1.74b (down 4.6% from FY 2020). Net income: NT$9.96m (down 96% from FY 2020). Profit margin: 0.6% (down from 14% in FY 2020). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jan 30Savior Lifetec Corporation Announces Change the Representative of Its Legal Person Director, Effective on February 1, 2022Savior Lifetec Corporation announced change the representative of the company's legal person director. Name of the previous position holder: LIN, MIN-SHIANG. Resume of the previous position holder: HUA ENG WIRE & CABLE CO., LTD. the representative of the director. Name of the new position holder: Wu Chia-Yu. Resume of the new position holder: HUA ENG WIRE & CABLE CO., LTD. Accounting Supervisor. Reason for the change: Change of representative of corporate director. On January 28, 2022, the company received a notice from the legal director Hua Eng Wire and Cable Co. Ltd. to change the representative, and it took effect on February 1, 2022.Reported Earnings • Nov 07Third quarter 2021 earnings released: NT$0.18 loss per share (vs NT$0.14 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$379.0m (down 12% from 3Q 2020). Net loss: NT$56.8m (down 226% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$0.084 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$523.6m (up 30% from 2Q 2020). Net income: NT$16.2m (down 30% from 2Q 2020). Profit margin: 3.1% (down from 5.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$34.00, the stock trades at a trailing P/E ratio of 38.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 22% over the past three years.分析記事 • Mar 29Is Savior Lifetec (GTSM:4167) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 20Full year 2020 earnings released: EPS NT$0.88 (vs NT$0.019 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.83b (up 39% from FY 2019). Net income: NT$250.9m (up NT$255.9m from FY 2019). Profit margin: 14% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.分析記事 • Feb 22Update: Savior Lifetec (GTSM:4167) Stock Gained 35% In The Last Five YearsWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...分析記事 • Jan 25Savior Lifetec Corporation (GTSM:4167) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?Savior Lifetec (GTSM:4167) has had a rough month with its share price down 23%. However, stock prices are usually...Is New 90 Day High Low • Jan 15New 90-day low: NT$29.85The company is down 6.0% from its price of NT$31.85 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.分析記事 • Dec 29Should You Use Savior Lifetec's (GTSM:4167) Statutory Earnings To Analyse It?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...Is New 90 Day High Low • Dec 25New 90-day high: NT$35.75The company is up 10.0% from its price of NT$32.40 on 25 September 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.分析記事 • Dec 03Savior Lifetec (GTSM:4167) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS NT$0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$429.3m (up 26% from 3Q 2019). Net income: NT$45.0m (up NT$43.1m from 3Q 2019). Profit margin: 11% (up from 0.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Oct 22New 90-day low: NT$31.20The company is down 7.0% from its price of NT$33.50 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Savior Lifetec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:4167 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,171242-468-346N/A12/31/20251,202537-164-21N/A9/30/20251,15949683222N/A6/30/20251,20945982239N/A3/31/20251,222497279407N/A12/31/20241,217182400518N/A9/30/20241,258180404475N/A6/30/20241,213121461503N/A3/31/20241,088104451491N/A12/31/20231,05030371388N/A9/30/2023986-55282297N/A6/30/20231,04794520538N/A3/31/20231,18088472500N/A12/31/20221,26636548582N/A9/30/20221,34748534583N/A6/30/20221,378-142186243N/A3/31/20221,545-124-2842N/A12/31/20211,74410-264-168N/A9/30/20211,976131-394-248N/A6/30/20212,026233-369-207N/A3/31/20211,904240-1861N/A12/31/20201,827251-12591N/A9/30/20201,63620134251N/A6/30/20201,5481586247N/A3/31/20201,450100104331N/A12/31/20191,319-5N/A156N/A9/30/20191,194-159N/A176N/A6/30/20191,113-257N/A-46N/A3/31/20191,122-275N/A-188N/A12/31/20181,105-360N/A-190N/A9/30/20181,173-300N/A-224N/A6/30/20181,302-187N/A-2N/A3/31/20181,432-89N/A104N/A12/31/20171,61822N/A261N/A9/30/20171,78195N/A272N/A6/30/20171,80130N/A158N/A3/31/20171,704-77N/A5N/A12/31/20161,532-208N/A-76N/A9/30/20161,303-389N/A-266N/A6/30/20161,185-457N/A-404N/A3/31/20161,127-494N/A-444N/A12/31/20151,121-494N/A-416N/A9/30/20151,195-424N/A-245N/A6/30/20151,119-443N/A-181N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4167の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4167の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4167の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4167の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4167の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4167の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 12:07終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Savior Lifetec Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yenya KuoCapital Securities CorporationXiaowei HuangMasterlink Securities Investment Advisory
Reported Earnings • May 18First quarter 2026 earnings released: EPS: NT$0.29 (vs NT$1.22 in 1Q 2025)First quarter 2026 results: EPS: NT$0.29 (down from NT$1.22 in 1Q 2025). Revenue: NT$233.6m (down 12% from 1Q 2025). Net income: NT$90.2m (down 77% from 1Q 2025). Profit margin: 39% (down from 146% in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 17Full year 2025 earnings released: EPS: NT$1.72 (vs NT$0.57 in FY 2024)Full year 2025 results: EPS: NT$1.72 (up from NT$0.57 in FY 2024). Revenue: NT$1.20b (down 1.3% from FY 2024). Net income: NT$537.4m (up 195% from FY 2024). Profit margin: 45% (up from 15% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$20.80, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 11% over the past three years.
お知らせ • Mar 06Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026. Location: 2 floor no,26, nan k`o 3rd rd., tainan city Taiwan
New Risk • Nov 24New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 154% Dividend yield: 2.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risk Dividend is not well covered by cash flows (154% cash payout ratio).
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: NT$0.26 (vs NT$0.14 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.26 (up from NT$0.14 in 3Q 2024). Revenue: NT$282.5m (down 15% from 3Q 2024). Net income: NT$79.9m (up 87% from 3Q 2024). Profit margin: 28% (up from 13% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 15Second quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.069 profit in 2Q 2024)Second quarter 2025 results: NT$0.05 loss per share (down from NT$0.069 profit in 2Q 2024). Revenue: NT$335.5m (down 3.8% from 2Q 2024). Net loss: NT$16.9m (down 177% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Jun 28Dividend increased to NT$0.41Dividend of NT$0.41 is 381% higher than last year. Ex-date: 14th July 2025 Payment date: 5th August 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Payout Ratios Payout ratio: 15%. Cash payout ratio: 10%.
New Risk • May 31New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 108% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • May 17First quarter 2025 earnings released: EPS: NT$1.22 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$1.22 (up from NT$0.22 in 1Q 2024). Revenue: NT$263.9m (up 1.8% from 1Q 2024). Net income: NT$386.1m (up 443% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 25Savior Lifetec Corporation to Report Q1, 2025 Results on May 02, 2025Savior Lifetec Corporation announced that they will report Q1, 2025 results on May 02, 2025
お知らせ • Apr 11Savior Lifetec Corporation Obtains Approval for Marketing in China and Obtains Drug LicenseSavior Lifetec Corporation obtained approval for marketing in China and obtained drug license. SLC's generic drug Ertapenem Sodium for Injection has been approved for drug registration by the NMPA of China, and a drug registration certificate has been obtained. This product is a carbapenem used for the treatment of complicated infections caused by multidrug-resistant bacteria. Indications of the product include: Complicated intra-abdominal infection, Community-acquired pneumonia, Acute pelvic infection, Complicated urinary tract infection, and Complicated skin and soft tissue infection. This product is the first to receive a drug registration certificate in the China market for the Company.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$15.90, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 12% over the past three years.
New Risk • Apr 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 30Full year 2024 earnings released: EPS: NT$0.57 (vs NT$0.095 in FY 2023)Full year 2024 results: EPS: NT$0.57 (up from NT$0.095 in FY 2023). Revenue: NT$1.22b (up 16% from FY 2023). Net income: NT$182.4m (up NT$152.4m from FY 2023). Profit margin: 15% (up from 2.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 07Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025. Location: 2 floor no,26, nan k`o 3rd rd., tainan city Taiwan
お知らせ • Feb 27Savior Lifetec Corporation to Report Fiscal Year 2024 Results on Mar 06, 2025Savior Lifetec Corporation announced that they will report fiscal year 2024 results on Mar 06, 2025
Buy Or Sell Opportunity • Feb 11Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jan 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.4% to NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.052 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.052 loss in 3Q 2023). Revenue: NT$332.5m (up 16% from 3Q 2023). Net income: NT$42.7m (up NT$59.2m from 3Q 2023). Profit margin: 13% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.016 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.07 (up from NT$0.016 in 2Q 2023). Revenue: NT$348.7m (up 56% from 2Q 2023). Net income: NT$21.9m (up 335% from 2Q 2023). Profit margin: 6.3% (up from 2.3% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat.
お知らせ • Aug 01Savior Lifetec Corporation to Report Q2, 2024 Results on Aug 08, 2024Savior Lifetec Corporation announced that they will report Q2, 2024 results on Aug 08, 2024
Buy Or Sell Opportunity • Jul 09Now 25% undervaluedOver the last 90 days, the stock has risen 7.8% to NT$23.45. The fair value is estimated to be NT$31.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% over the last 3 years. Earnings per share has declined by 38%.
Declared Dividend • Jun 28Dividend reduced to NT$0.085Dividend of NT$0.085 is 18% lower than last year. Ex-date: 12th July 2024 Payment date: 5th August 2024 Dividend yield will be 0.3%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 26%. Cash payout ratio: 6%.
お知らせ • Jun 27Savior Lifetec Corporation Approves the Cash Dividend, Payable on August 05, 2024Savior Lifetec Corporation at its shareholders’ meeting held on June 26, 2024, approved the cash dividend of TWD 0.0851 per share will be distributed, totaling TWD 27,027,002. Ex-rights (Ex-dividend) date: July 12, 2024. Ex-rights (Ex-dividend) record date: July 20, 2024. Payment date of cash dividend distribution: August 05, 2024.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.22 (vs NT$0.011 loss in 1Q 2023)First quarter 2024 results: EPS: NT$0.22 (up from NT$0.011 loss in 1Q 2023). Revenue: NT$259.2m (up 17% from 1Q 2023). Net income: NT$71.1m (up NT$74.6m from 1Q 2023). Profit margin: 27% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 28Savior Lifetec Corporation to Report Q1, 2024 Results on May 03, 2024Savior Lifetec Corporation announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 03, 2024
New Risk • Mar 26New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 21Full year 2023 earnings released: EPS: NT$0.09 (vs NT$0.12 in FY 2022)Full year 2023 results: EPS: NT$0.09 (down from NT$0.12 in FY 2022). Revenue: NT$1.05b (down 17% from FY 2022). Net income: NT$30.0m (down 18% from FY 2022). Profit margin: 2.9% (in line with FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 09Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024. Location: 2F., No. 26, Nanke 3rd Rd., Xinshi Dist., Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 distributable compensation for employees and directors; to consider 2023 Annual Earnings Cash Dividend Distribution Report; to consider Audit Committee’s Review Report; to consider 2023 Business Report and Financial Statements; to consider Company's 2023 earnings distribution; and to consider Lifting the non-competition restriction case of the company’s directors.
Reported Earnings • Nov 11Third quarter 2023 earnings released: NT$0.05 loss per share (vs NT$0.42 profit in 3Q 2022)Third quarter 2023 results: NT$0.05 loss per share (down from NT$0.42 profit in 3Q 2022). Revenue: NT$287.2m (down 18% from 3Q 2022). Net loss: NT$16.5m (down 112% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$21.35, the stock trades at a trailing P/E ratio of 71.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 32% over the past three years.
Reported Earnings • Aug 05Second quarter 2023 earnings released: EPS: NT$0.02 (vs NT$0.005 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.02 (up from NT$0.005 loss in 2Q 2022). Revenue: NT$223.2m (down 37% from 2Q 2022). Net income: NT$5.03m (up NT$6.56m from 2Q 2022). Profit margin: 2.3% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 29Upcoming dividend of NT$0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 03 August 2023. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.6%).
Reported Earnings • Mar 16Full year 2022 earnings released: EPS: NT$0.11 (vs NT$0.031 in FY 2021)Full year 2022 results: EPS: NT$0.11 (up from NT$0.031 in FY 2021). Revenue: NT$1.27b (down 27% from FY 2021). Net income: NT$36.4m (up 266% from FY 2021). Profit margin: 2.9% (up from 0.6% in FY 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 07Second quarter 2022 earnings released: NT$0.005 loss per share (vs NT$0.051 profit in 2Q 2021)Second quarter 2022 results: NT$0.005 loss per share (down from NT$0.051 profit in 2Q 2021). Revenue: NT$356.1m (down 32% from 2Q 2021). Net loss: NT$1.53m (down 109% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Aug 06Savior Lifetec Corporation Appoints as Xu Fang Zhen Head of Internal AuditSavior Lifetec Corporation appointed as Xu Fang Zhen Head of Internal Audit. Name, title, and resume of the new position holder: XU FANG ZHEN, internal audit officer /Deputy Audit Manager of UNISON COMPANY LTD. Effective date is August 5, 2022.
お知らせ • Jun 02Savior Lifetec Corporation Announces Appointment of Cheng, Chin-Hwa as Member of the Audit CommitteeSavior Lifetec Corporation announced changes in the members of the audit committee with appointment of Cheng, Chin-Hwa as new member . Date of change is June 1 2022. Resume of the new position holder: Independent director of Chongdah health co. Ltd.
Reported Earnings • May 08First quarter 2022 earnings released: NT$0.17 loss per share (vs NT$0.25 profit in 1Q 2021)First quarter 2022 results: NT$0.17 loss per share (down from NT$0.25 profit in 1Q 2021). Revenue: NT$307.3m (down 39% from 1Q 2021). Net loss: NT$54.0m (down 168% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 16Savior Lifetec Corporation Approves the Appointment of Cheng, Chin-Hwa as Members of the Compensation CommitteeSavior Lifetec Corporation approved the appointment of Cheng, Chin-Hwa as members of the compensation Committee. Resume of the new position holder: Independent director of Chongdah health co. Ltd. Effective date of the new member is April 15, 2022.
Reported Earnings • Mar 13Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: NT$0.03 (down from NT$0.84 in FY 2020). Revenue: NT$1.74b (down 4.6% from FY 2020). Net income: NT$9.96m (down 96% from FY 2020). Profit margin: 0.6% (down from 14% in FY 2020). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jan 30Savior Lifetec Corporation Announces Change the Representative of Its Legal Person Director, Effective on February 1, 2022Savior Lifetec Corporation announced change the representative of the company's legal person director. Name of the previous position holder: LIN, MIN-SHIANG. Resume of the previous position holder: HUA ENG WIRE & CABLE CO., LTD. the representative of the director. Name of the new position holder: Wu Chia-Yu. Resume of the new position holder: HUA ENG WIRE & CABLE CO., LTD. Accounting Supervisor. Reason for the change: Change of representative of corporate director. On January 28, 2022, the company received a notice from the legal director Hua Eng Wire and Cable Co. Ltd. to change the representative, and it took effect on February 1, 2022.
Reported Earnings • Nov 07Third quarter 2021 earnings released: NT$0.18 loss per share (vs NT$0.14 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$379.0m (down 12% from 3Q 2020). Net loss: NT$56.8m (down 226% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$0.084 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$523.6m (up 30% from 2Q 2020). Net income: NT$16.2m (down 30% from 2Q 2020). Profit margin: 3.1% (down from 5.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$34.00, the stock trades at a trailing P/E ratio of 38.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 22% over the past three years.
分析記事 • Mar 29Is Savior Lifetec (GTSM:4167) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 20Full year 2020 earnings released: EPS NT$0.88 (vs NT$0.019 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.83b (up 39% from FY 2019). Net income: NT$250.9m (up NT$255.9m from FY 2019). Profit margin: 14% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
分析記事 • Feb 22Update: Savior Lifetec (GTSM:4167) Stock Gained 35% In The Last Five YearsWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...
分析記事 • Jan 25Savior Lifetec Corporation (GTSM:4167) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?Savior Lifetec (GTSM:4167) has had a rough month with its share price down 23%. However, stock prices are usually...
Is New 90 Day High Low • Jan 15New 90-day low: NT$29.85The company is down 6.0% from its price of NT$31.85 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.
分析記事 • Dec 29Should You Use Savior Lifetec's (GTSM:4167) Statutory Earnings To Analyse It?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...
Is New 90 Day High Low • Dec 25New 90-day high: NT$35.75The company is up 10.0% from its price of NT$32.40 on 25 September 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.
分析記事 • Dec 03Savior Lifetec (GTSM:4167) Seems To Use Debt Quite SensiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS NT$0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$429.3m (up 26% from 3Q 2019). Net income: NT$45.0m (up NT$43.1m from 3Q 2019). Profit margin: 11% (up from 0.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Oct 22New 90-day low: NT$31.20The company is down 7.0% from its price of NT$33.50 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.